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Abstract
Purpose—The current study evaluated associative effects of breast cancer cells with the tumor 
microenvironment and its influence on tumor behavior.
Experimental design—Formalin-fixed paraffin embedded tissue and matched protein lysates 
were evaluated from two independent breast cancer patient data sets (TCGA and MD Anderson). 
Reverse-phase protein arrays (RPPA) were utilized to create a proteomics signature to define 
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breast tumor subtypes. Expression patterns of cell lines and normal breast tissues were utilized to 
determine markers that were differentially expressed in stroma and cancer cells. Protein 
localization and stromal contents were evaluated for matched cases by imaging.
Results—A subtype of breast cancers designated “Reactive,” previously identified by RPPA that 
was not predicted by mRNA profiling, was extensively characterized. These tumors were primarily 
estrogen receptor (ER)-positive/human epidermal growth factor receptor (HER)2-negative, low-
risk cancers as determined by enrichment of low-grade nuclei, lobular or tubular histopathology, 
and the luminal A subtype by PAM50. Reactive breast cancers contained high numbers of stromal 
cells and the highest extracellular matrix content typically without infiltration of immune cells. For 
ER-positive/HER2-negative cancers, the Reactive classification predicted favorable clinical 
outcomes in the TCGA cohort (HR = 0.36, P < 0.05).
Conclusions—A protein stromal signature in breast cancers is associated with a highly 
differentiated phenotype. The stromal compartment content and proteins are an extended 
phenotype not predicted by mRNA expression that could be utilized to sub-classify ER-positive/
HER2-negative breast cancers.
Keywords
intra-tumoral stroma; reactive; breast cancer classification; lobular; overtreatment
Introduction
Molecular stratification by mRNA has identified multiple subtypes of breast cancers that can 
predict outcomes independently of clinical characteristics and standard protein biomarkers 
(1,2). These molecular subtypes of cancer were reported to be associated with tumor 
microenvironments of different tumor and stromal cell contents and expression of 
extracellular matrix mRNA and proteins (3,4). In fact, rigorous morphological evaluation of 
the tumor microenvironment was reported to provide similar prognostic information content 
relative to the cancer epithelium itself (5). However, the criteria used to evaluate the tumor 
microenvironment are not well established and thus are not universally applied, particular in 
the clinical management of tumors. Also, it is unclear mechanistically how characteristics of 
the tumor microenvironment influence patient outcomes. Some reports with multiple 
malignancies including lung, colon, and gastric cancer suggested that higher quantities of 
intra-tumoral stromal and myofibroblast contents were associated with worse clinical 
outcomes and metastasis (6-8). In breast cancer, conflicting imaging studies have been 
published on stromal content and prognosis. For ER-positive breast cancers, improved 
outcomes were associated with increased stromal content (9). In contrast, a high stromal 
content predicted poor survival in triple-negative breast cancers (10-13). These clinical 
studies of breast cancer microenvironment, with outcome as the primary endpoint, may have 
confounding results because of the presence of multiple molecular subtypes of epithelium, 
different clinical standard-of-care treatments, and different patient selection criteria.
Previously, we reported an RPPA subtype called “Reactive” breast cancer with high 
expression of extracellular matrix proteins (14,15). Herein we demonstrate that the Reactive 
subtype represents a more differentiated and relatively better-behaved disease, enriched in 
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lobular and luminal A breast cancers. Our data suggest that a high stromal protein signature 
marks fundamental biological differences between breast cancers and may help identify 
breast cancers with excellent prognosis.
Patients and Methods
Clinical samples and cell lines
Two independent sets of breast cancers with matched protein lysates and formalin-fixed, 
paraffin-embedded (FFPE) sections were utilized: TCGA (n = 885) and MDACC (n = 63). 
For the TCGA cohort, only a subset of cases with RPPA data was available with matched 
unstained FFPE sections (n = 109).
Breast cancer cell lines (T47D, MCF7) were obtained from the MD Anderson Characterized 
Cell Line Core facility (Houston, TX). The identities of all cell lines were verified using 
AmpF/STR Identifier kit (Applied Biosystems) by the core facility and used within 6 
months of obtaining the cell lines. The lines were cultured in DMEM supplemented with 5% 
fetal bovine serum (FBS) at 37°C in 5% carbon dioxide atmosphere. Cell lines were 
routinely tested for Mycoplasma infection using a MycoTect Kit (Invitrogen).
MDA-MB-134 (ATCC) and Sum44PE (Asterand) cells were cultured as previously 
described (16). The cell lines were authenticated annually by PCR RFLP analyses and 
confirmed to be Mycoplasma negative at the University of Pittsburgh Cell Culture and 
Cytogenetics Facility (Pittsburgh, PA).
Cancer tissues from the University of Utah (A.W.) were mastectomy specimens from 
patients without prior therapy. Normal specimens were collected from matched grossly 
uninvolved tissues. Tissues were collected and de-identified using approved IRB#10924.
Immunohistochemistry and imaging studies
Board-certified pathologists blinded to the RPPA results performed the histopathology 
classification and the manual scoring of sections. Manual scoring by pathologists for the 
TCGA cohort was performed using α-SMA (R.E.B.) and H&E stained sections (TCGA 
pathology team). For the H&E scored cases of the TCGA, epithelial content was reported as 
follows: proportion of epithelium in invasive portion by area (excluding areas of necrosis): 
<25% (Low; score 1), 25-75% (Moderate; score 2), >75% (High; score 3). To obtain scores 
for the intra-tumoral stroma (ITS) of the TCGA cases by H&E, the epithelial content values 
were converted to stromal content; score 1 was converted to score 3, and score 2 was 
unchanged. Nottingham grade for the TCGA cases was a combined score of epithelial tubule 
formation, mitosis, and nuclear pleomorphism (3 each for a maximum total score of 9, score 
was separated into three bins: [1] 3,4; [2] 5,6,7; [3] 8,9).
The stromal content using H&E stained sections (MDACC cohort) or α-SMA stained 
sections (TCGA cohort) were quantified by imaging (InForm 2.0) similar to methods 
previously described (17). FFPE tumor sections were first scanned at low power (40x) to 
identify tissue and then high-powered field (HPF) images (n = 50 maximum) were collected 
randomly across the whole section at 200x magnification (Vectra 2.0, Perkin Elmer). All 
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fields of invasive cancer without edge effects, normal tissue, or necrosis were selected for 
scoring by an investigator blinded to the identities of the cases.
Unstained sections from selected matched TCGA cases were used for 
immunohistochemistry staining of various proteins. Slides were dried at 60°C, 
deparaffinized in xylene, quenched in 3% hydrogen peroxide/methanol for 10 min, and 
rehydrated through sequentially graded ethanol. Antigen retrieval was performed by EDTA 
incubation (1 mmol/L, pH 8.0) using a pressure cooker at 125°C/25 psi for 5 min. Slides 
were cooled for 20 min, rinsed with distilled water, and washed in Tris-buffered saline. 
Using a DAKO Autostainer (DAKO, Carpinteria, CA), the slides were blocked for 30 min in 
horse serum and incubated with primary antibody for 1 h. Primary antibodies were matched 
to the RPPA platform: Caveolin-1 (1:200), E-cadherin (1:200), and RBM15 (1:1000). The 
Universal ABC Elite kit (Vectastain, Burlingame, CA) with 3,3′-diaminobenzidine 
development was used to visualize antibody binding, and the slides were counterstained with 
hematoxylin. For α-SMA staining, slides were incubated for 20 min at room temperature 
with primary antibody, Dako M0851 (mouse, clone 1A4), 1:500 dilution and developed 
using polymer-HRP and 3,3′-diaminobenzidine per the manufacturer's instructions 
(PowerVision+, Leica PV6104). Breast cancer tissues without primary antibody incubation 
were utilized as negative controls.
Reverse-phase protein array (RPPA)
Lysates from flash-frozen tissues from the TCGA and MDACC cohorts were prepared and 
analyzed by RPPA as described previously (14). For the MDACC cohort, H&E sections 
were obtained from each flash frozen tissue. Using these sections, a pathologist (A.S.) 
verified the flash frozen tissue was invasive carcinoma prior to RPPA protein lysate 
preparation of the frozen tissue.
Analytical and statistical methods
mRNA and protein expression differences between breast cancers and cell lines were 
assessed using Student's t-tests and one-way ANOVA. Survival curves were determined 
using the Kaplan-Meier method, and differences between groups were evaluated using the 
Log-rank test. The association between sample cluster (Cluster II and Other) and clinical 
factors was detected using chi-square test. Statistical analyses were performed using Prism 
5.0c (GraphPad Software, La Jolla, CA) or R, version 2.15.1 (http://www.r-project.org/). 
Consensus clustering was performed using R, and heatmaps were generated using an R-
package NGCHM (see Supplementary materials). P ≤ 0.05 (two-sided) was considered 
significant.
Results
Identification of Reactive breast cancer subtype by RPPA
RPPA analyses were performed on breast cancer protein lysates from two independent 
cohorts from the TCGA and the University of Texas MD Anderson Cancer Center (MDACC 
cohort). For the TCGA cohort, a subset was previously evaluated as an individual cohort (n 
= 403) (14) and included as part of a combined pan-cancer analysis (n = 747) (15); however, 
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the current set is expanded (n = 885) and analyzed independently of other malignancies. 
Four groups were evident by consensus clustering including two primarily ER-positive, one 
HER2-positive, and one basal-like group (Supplementary Fig. S1). To evaluate the key 
features of the RPPA subtypes, a small percentage of the TCGA cases without strong 
statistical association to any cluster were removed to generate a core group of TCGA cases 
(n = 774) (Fig. 1A, see Supplementary Materials).
Previously, we reported Cluster II (Fig. 1A, Supplementary Fig. S1) of the TCGA cohort as 
two separate “Reactive” breast cancer subtypes (14). These two groups within Cluster II 
were still evident in the entire cohort (Supplementary Fig. S1) and to a lesser extent in the 
core cohort (Fig. 1A). However, because these two groups were defined by a single set of 
markers with a graded expression, we evaluated them as one subtype termed “Reactive” for 
this manuscript and recommend that they be considered as a single group in future studies. 
Prediction models using RPPA protein expression data were highly effective in identifying 
Cluster II (Reactive) breast cancers for all core cases and the ER-positive/HER2-negative 
group (Supplementary Tables 1 and 2, see Supplementary Materials). For the ER-positive/
HER2-negative group, key determinants positively associated were annexin-1, collagen VI, 
and HSP70 and negatively associated were BAP1, phosphomyosinIIA, and PRDX1 with 
more modest contributions from phosphoERalpha and GATA3.
Reactive (Cluster II) cases were mostly ER-positive (82%) and were distinctive from other 
ER-positive cases in Cluster I (99% ER-pos, Fig. 1A). The Reactive subtype was also 
enriched in lobular cancers and thus CDH1 mutations and low-risk characteristics of breast 
cancers including low Nottingham grade, luminal A breast cancers, and wild-type TP53 
(Table 1). Importantly, this enrichment of characteristics for Reactive breast cancers was still 
maintained within the ER-positive/HER2-negative clinical subtype (Table 1). These data 
suggest that the Reactive breast cancer subtype is independent of the existing clinical protein 
biomarkers (ER and HER2).
By RPPA analysis, Reactive breast cancer was a distinctive group of cancers with relatively 
high expression of stromal proteins such as collagen-VI. Surprisingly, the cancers expressed 
lower levels of proteins associated with ER-positive breast cancer such as ER-alpha and 
GATA3 as compared to Cluster I (Fig. 1B, Supplementary Table 3, Supplementary Fig. S2) 
even though the Reactive cancers were ER-alpha positive as determined by clinical criteria. 
Thus, we hypothesized that epithelial-derived proteins such as ER-alpha were diluted by 
extracellular matrix (ECM) proteins or by increased numbers of stromal cells.
To test this hypothesis, localization and relative expression of selected proteins by 
immunohistochemistry were evaluated for representative IDC (invasive ductal carcinoma) 
cases using the same antibodies as the RPPA assays: caveolin-1 (high in Reactive group, Fig. 
1A and 1B), E-cadherin (low in Reactive group, Fig. 1A), and RBM15 (low in Reactive 
group, Fig. 1A and 1B). For all three proteins, the expression patterns and intensities were 
consistent with a higher amount of stromal cells and/or ECM diluting the epithelium in 
Reactive breast cancers (Supplementary Fig. S3 to S5). Caveolin-1 was exclusively 
expressed in the stromal compartment for luminal and Reactive cancers (Supplementary Fig. 
S3). E-cadherin was expressed by epithelium in the cell membrane of all IDC cases without 
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an apparent difference in intensity in the tumor cells between luminal and Reactive breast 
cancers (Supplementary Fig. S4). A decreased number of cancer cells with an increase in 
ECM could contribute to low total lysate levels of RBM15 because the protein was equally 
expressed and localized to the nucleus of all cells independently of RPPA subtype 
(Supplementary Fig. S5). In support of an epithelial protein dilution effect, mRNA profiling 
approaches like the PAM50 have not previously associated the RPPA Reactive subtype with 
high stromal marker expression. In our study, the mRNA expression levels of caveolin-1, 
collagen VI, ER-alpha, and RBM15 were highly variable between the RPPA subtypes 
(Supplementary Fig. S6A) and not predictive of protein content especially within the Cluster 
II/Reactive subtype (Supplementary Fig. S6B).
To further confirm that Reactive cases were enriched in stromal proteins, the RPPA proteins 
on the platform were first classified as primarily “stroma” or ER-positive breast “cancer” 
derived. To classify the proteins, expression patterns of normal breast tissues were compared 
to those of ER-positive breast cancer cell lines including representative IDC and invasive 
lobular carcinoma (ILC) cell lines (Supplementary Fig. S7, Supplementary Table 4). Normal 
breast tissues were chosen as the stromal-enriched tissue because at least 70% of non-fatty 
areas in normal tissue are composed of stroma rather than epithelium by imaging (18). The 
results of IDC and ILC comparisons to normal breast tissue were aligned with two 
exceptions; cell junction proteins, E-cadherin and β-catenin, were characteristically low in 
lobular breast cancer. Using these protein classifications, RPPA expression patterns of 
Cluster II were confirmed to be highly associated with stromal proteins and reduced 
expression of cancer cell proteins for the TCGA cohort (Supplementary Fig. S8).
Patient outcomes for Reactive breast cancers
To evaluate the clinical impact of cancers with high expression of stromal proteins, patient 
outcomes were evaluated within the RPPA subtypes; Reactive breast cancers had the best 
outcomes while the basal subtype had the worst clinical outcomes (Fig. 1C). As expected 
when including triple-negative and HER2-positive cancers, poor outcomes were also highly 
associated with high-risk characteristics of breast cancers including tumor size, 
histopathology, Nottingham grade, lymph node status, and PAM50 classification (Table 2). 
However, within the ER-positive/HER2-negative clinical subtype, only young age and the 
RPPA Reactive breast cancer subtype predicted improved survival outcomes demonstrating 
the potential utility of RPPA subtyping within this highly relevant clinical subtype (Table 2). 
Interestingly, RPPA Reactive subtyping also stratified ILC risk in terms of outcomes 
although the total events for ILC cases were low for the TCGA cohort (log-rank P-value = 
0.019; 0 events for Reactive, n = 77, versus 4 events for non-Reactive, n = 63).
Stromal content by quantitative imaging of breast cancers
To confirm that the Reactive breast cancers were higher in stromal content, matched cases 
from the TCGA were evaluated by imaging (Fig. 2). To perform a quantitative evaluation of 
the cases for stromal content including area and cell count, representative matched sections 
from the TCGA cohort were stained with α-SMA to mark cells within the stromal 
compartment (myofibroblasts, carcinoma-associated fibroblasts). All available cases for ILC 
and representative IDC cases from each RPPA subtype of the TCGA cohort were stained and 
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evaluated. InForm Vectra software was utilized for compartment segmentation and cellular 
counting for multiple high-powered fields randomly selected across the sections (Fig. 2A, 
Supplementary Fig. S9). The stromal content both by area (Fig. 2B) and by cell count (Fig. 
2C) were approximately 2-fold higher within the RPPA Reactive breast cancer subtypes as 
compared to luminal for both ILC and IDC cases. Consistent with the clustering results (Fig. 
1A), the amount of stromal content within the RPPA subtypes was independent of ILC or 
IDC classification (Fig. 2B and 2C). These results also demonstrated that RPPA basal-like 
breast cancers contained the lowest quantity of stroma both by area and cell counting (Fig. 
2B and 2C).
To validate the findings from the TCGA cohort, cases from an independent MDACC cohort 
of ER-positive/HER2-negative cancers were similarly evaluated by RPPA and by imaging. 
Like that observed for the TCGA cohort, consensus clustering of MDACC cases revealed 
two primary clusters including a subtype enriched in stromal proteins, Reactive breast cancer 
(Supplementary Fig. S10A and 10B, Supplementary Table 3). The differences in ER protein 
expression between the two subtypes were evaluated by comparing the % positivity of ER 
by IHC (Supplementary Fig. S10C). While the %ER positivity was statistically lower in the 
Reactive subtype, this difference was caused primarily by 5 cases with the lowest %ER 
expression (<50%); most Reactive cancers were highly ER-positive (80 to 100%). Higher 
stromal content by area in the Reactive subtype was confirmed by imaging in the ER-
positive/HER2-negative MDACC cohort (Supplementary Fig. S10D). The highest stromal 
contents were also associated with normal breast, ILC, and lower nuclear grade cases 
(Supplementary Fig. S10D).
To evaluate whether there were qualitative differences in the stromal compartment, we 
calculated the cell density within the cancer cell and stromal compartments for the TCGA 
cohort (Supplementary Fig. S11A). As expected, the stromal compartment cell density was 
much less cell-enriched as compared to the cancer compartment (25% of the cancer 
compartment on average, Supplementary Fig. S11A). While no differences were observed 
within the cancer compartment (Supplementary Fig. S11B), the stromal cell density was 
higher in the Reactive breast cancer subtype of ILC cases but not for IDC cases (Fig. 2D). 
However, the stromal compartments of the basal-like IDC cases were on average less 
stromal-cell enriched than the luminal IDC cases (Fig. 2D). These data suggest that the 
stromal cell concentration is different between RPPA subtypes, not just the amount of ECM, 
although stromal cell concentration and ECM may be associated with one another.
To further characterize the stroma, we also evaluated myofibroblast content by quantifying 
the staining intensity of α-SMA. Interestingly, the highest α-SMA staining (3+) was 
observed for some of the ILC cases within the Reactive subtype (Supplementary Fig. S11C, 
S11D, S11E, and S12). However, consistent with previous studies (19), there was substantial 
variability in SMA staining (Supplementary Fig. S11C). No differences in α-SMA staining 
were detected between RPPA subtypes for the IDC cases (Supplementary Figs. S11C and 
S13).
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mRNA/DNA signatures of stromal characteristics for Reactive breast cancer
Given that a higher density and the effective overall number of stromal cells were increased 
in the RPPA Reactive subtype, we hypothesized that Reactive breast cancer may have altered 
mRNA and/or DNA cell-based scores (ABSOLUTE, ESTIMATE) based on approaches used 
to evaluate stromal content and cell types including purity measures, proliferation, and 
immune cell contents as defined previously (4,15,20,21). We evaluated the association of 
these scores to RPPA subtyping of breast cancer within histopathology groups (ILC and 
IDC, Supplementary Fig. S14). For IDC and sometimes ILC cases, Reactive breast cancers 
were statistically less pure and contained higher stromal content using DNA- or mRNA-
derived scores (Supplementary Fig. S14A, S14B, S14C, S14D, and S14E). However, purity 
and stromal content scores were not sufficient to identify Reactive breast cancers. 
Furthermore, the differences between the luminal and Reactive breast cancer subtypes were 
minor (7% difference for ABSOLUTE scores, Supplemental Supplementary Fig. S14A), and 
the standard deviations of the scores were high between subtypes (ESTIMATE scores, 
Supplemental Supplementary Fig. S14B).
Because high epithelial mesenchymal transition (EMT) scores may suggest a higher 
mesenchymal cell content, mRNA-derived EMT scores (22) were evaluated for the RPPA 
subtypes. As expected for cancers with a high fibroblast content, Reactive breast cancers had 
the highest EMT scores as compared to all other subtypes including luminal, HER2, and 
basal subtypes (Supplementary Fig. S14D). These associations were independent of 
histopathology demonstrating that loss of E-cadherin in ILC cases did not explain the high 
EMT scores. This result is also consistent with Reactive breast cancers as highly 
differentiated cancers, on the opposite end relative to the “claudin-low” cancers, a rare 
subtype in which the cancer cells themselves have EMT characteristics including loss of E-
cadherin (23).
We also evaluated immune infiltration for the Reactive subtype. Consistent with previous 
reports of tumor-infiltrating lymphocytes in triple-negative breast cancer (24), the RPPA 
subtype with the highest immune score was Cluster IV, which largely corresponds to PAM50 
basal-like breast cancers (Supplementary Fig. S14E and S14F). No differences between 
luminal and Reactive breast cancer subtypes were observed in immune response by immune 
response score (Supplementary Fig. S14E). Stromal lymphocytes were rare in ILC breast 
cancer in particular; only 8 events of immune infiltration were recorded for all the scored 
ILC cases (N = 73, Supplementary Fig. S14F).
Thus, the data suggest that mRNA scores for tumor purity, stromal content, or EMT trend in 
the expected direction but cannot effectively identify the RPPA-based Reactive breast cancer 
subtype. Also, Reactive breast cancers are not characterized by immune infiltration.
Intra-tumoral stromal (ITS) scoring to characterize breast cancers
In addition to our quantitative imaging evaluation of stromal content for selected cases, the 
stromal content could also be estimated by using intra-tumoral stromal (ITS) scores for 
almost the entire TCGA cohort. For matched cases, software quantification values of stromal 
areas were in good agreement with the manual scoring definitions (Fig. 2E, Spearman 
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correlation coefficient = 0.53, P = 0.001), but with these established limits, there were 
relatively few high “3” (>75% stroma by area) and low scores “1” (<25% stroma by area). 
Consistent with the software quantification, manual scoring of the ITS content demonstrated 
within IDC that RPPA Reactive breast cancers contained lower amounts of epithelium in the 
invasive part of the tumor (Fig. 2F). Although the trend was in the expected direction, the 
amounts of epithelium in ILC cases were not statistically different between the luminal and 
Reactive RPPA subtypes (Fig. 2F).
Morphology of IDC Reactive breast cancers
We used ITS scores to also understand the effects of histopathology and other clinical 
characteristics on the tumor microenvironment in the TCGA cohort. ER-pos/HER2-neg ILC 
contained higher quantities of stroma in the invasive part of the tumor as compared to IDC 
independently of ER status (Fig. 3A). Independent of histopathology, stromal contents of 
ER-pos/HER2-neg breast cancers were the lowest in cases predicted to be aggressive by 
nuclear scoring (Fig. 3B). Interestingly, this association was only evident for ER-pos/HER2-
neg tumors (not triple-negative or PAM50-defined basal-like cancers, data not shown).
In conjunction with high stromal content, evaluation of Reactive breast cancer morphology 
by imaging revealed that IDC Reactive breast cancers were highly differentiated cancers 
often with neoplastic tubule formation as compared to RPPA luminal and basal-like cancers 
(Fig. 3C and 3D and Supplementary Fig. S13). These differences were quantified by 
pathological scoring of neoplastic tubules for the TCGA cohort (Fig. 3E). Importantly, the 
other two scores used in combination to calculate the overall nuclear score for IDC cases 
(Fig. 3B) were not associated, or only weakly associated, with stromal content (nuclear 
pleomorphism and mitotic figures, Supplementary Fig. S15). While these neoplastic tubules 
in Reactive breast cancer were clearly cancerous, as shown by loss of myoepithelium (Fig. 
3C), these tumors were remarkably similar to normal breast tissue as shown by protein 
expression patterns by RPPA (Supplementary Fig. S16). The fact that normal breast tissues 
cluster with Reactive breast cancers by RPPA suggests that the cancer cells present in 
Reactive breast cancers do not substantially alter the protein composition of the stromal 
compartment, at least for the proteins included in the RPPA panel. The enrichment of 
PAM50 “normal-like” breast cancer within the Reactive subtype is also consistent with the 
normal, less aggressive behavior of Reactive breast cancers (Table 1).
Discussion
A number of pathological criteria have been used to assess risk of relapse or metastasis in 
breast cancer, such as differentiation and Nottingham grade of cancer cells. However, 
corresponding histological effects on the tumor microenvironment and of the 
microenvironment on outcomes have not been well evaluated. The interaction of cancer cells 
and the tumor microenvironment is a promising area of research because new biomarkers 
and therapeutics targets may be discovered that are not present in the cancer cells; a recent 
example being the development and promise of immune checkpoint inhibitors.
The current study evaluated histological and proteomics markers of the tumor 
microenvironment in breast cancer by utilizing cases from the TCGA supplemented by a 
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sample set from the MD Anderson Cancer Center for confirmation. We discovered a subtype 
of breast cancers that was uniquely defined only by protein expression. These “Reactive” 
cancers were typically ER-positive, low-risk, and also more likely to have high expression of 
stromal proteins. The Reactive subtype compared to other breast cancers also had higher 
intra-tumoral stromal volumes and increased cell densities within the stromal compartment. 
Importantly, patients with ER-positive/HER2-negative disease and a Reactive subtype 
signature had an excellent prognosis and thus would not likely benefit from additional 
therapies.
Multiple RPPA studies including our own (14,15,25) have previously reported a group of 
breast cancers with apparently high expression of stromal proteins such as collagen and 
caveolin-1. Previously, the biological significance of these findings was not understood; 
investigators speculated that high caveolin-1 expression was related to loss of expression in 
the microenvironment of more aggressive cancers (25). Our study points to increased 
stromal content, not loss of caveolin-1 in the tumor microenvironment, as a major cause for 
this observation. In addition, the stroma itself had a higher cell density on average in 
Reactive breast cancers.
From our study, we now understand that the presence of high intra-tumoral stroma with 
highly differentiated cancer cells is a fundamental property of Reactive breast cancers. 
While it might be tempting to draw conclusions about the “protective” nature of the stromal 
compartment in the metastasis potential of Reactive breast cancers, clinical outcomes are 
confounded by fundamental differences in cancer cell biology (i.e. luminal A enrichment). 
We know that breast cancer cells with high intra-tumoral stromal content are slowly 
dividing, so a higher stromal content may simply be a result of increased ratios of replication 
rates for fibroblasts versus cancer cells. Consistent with this hypothesis, fast-growing animal 
tumor models including patient-derived xenograft models of breast cancer have low stromal 
content. From our study data, we cannot make any assessments on the role of myofibroblasts 
or stromal proteins such as suggested for collagen VI in the metastasis of breast cancers 
(26). However, we can say that the presence of high ECM content and/or a high number of 
stromal cells by itself (and not immune cells) did not increase the probability of relapse in 
breast cancer and further were associated with an improved outcome. These effects on 
outcomes appear to be contextual because opposite associations with outcomes have been 
reported for other cancers such as gastric cancer (6-8).
Strengths of the current work are the size and comprehensive molecular and pathological 
classifications available for the TCGA cohort. We were able to use case-matched protein 
array, gene array, and imaging data to demonstrate the fundamental differences between the 
Reactive subtype and other breast cancer tumors. We were also able to validate many of the 
key findings with an independent MDACC cohort. While this MDACC validation cohort had 
few events and was unable to verify the clinical outcomes endpoint, other clinical data 
previously published confirmed our findings of improved outcomes for ER-positive breast 
cancers with a high stromal content assessed by imaging (9).
As compared to our results for ER-positive cancers, the findings in the literature are 
contradictory for ER-negative breast cancers. Other investigators have reported that a high 
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stromal content by an mRNA signature or imaging is associated with resistance to 
chemotherapy and worse clinical outcomes (10-13,21). While these reports may seem in 
conflict with our results, breast cancers that are less “basal-like” would be expected to be 
more chemotherapy resistant and per our results, to have a higher stromal content. For triple-
negative breast cancers, more late relapses might also be expected for less “basal-like” breast 
cancers like those observed for luminal breast cancer within the triple-negative clinical 
subtype, which can represent up to 25% of all triple-negative breast cancers (27). However, 
we were unable to confirm the results of other studies using data from the TCGA cohort; 
ER-negative/HER2-negative cancers with high stromal content by manual scoring were rare 
in the TCGA cohort (<4%). Also, Reactive subtyping did not predict clinical outcomes in 
ER-negative/HER2-negative disease (data not shown). Thus, our data does not support a 
clinical value for Reactive subtyping for triple-negative breast cancers.
Our study indicates that one possible clinical use for Reactive subtyping would be the sub-
classification of ER-positive/HER2-negative breast cancers (Table 2). While we were unable 
to directly compare the results of Reactive subtyping to Oncotype-DX, we were able to show 
differences between RPPA and mRNA classification by PAM50. Other studies using mRNA 
to evaluate stromal content were consistent with our results; high collagen mRNA 
expression patterns were associated with ER-positive/low-grade breast cancers (3). However, 
we were unable to reproduce these results using the data from the TCGA cohort (data not 
shown). The variability in the stromal mRNA scoring of the TCGA cohort suggests that 
protein assays may more reliably classify breast cancers when it comes to assessing stromal 
features.
At this time, it is unclear what would be the most effective biomarker to identify Reactive 
breast cancers in the clinic. While RPPA profiling was effective in a highly controlled, 
translational study like the TCGA, we demonstrated that normal breast tissue and the 
Reactive subtype have similar protein profiles (Supplementary Fig. S16), and thus, 
contamination with normal tissue could reduce specificity in RPPA assays (or other protein 
assays) and cause many more breast cancers to artificially appear Reactive. Although IHC 
can easily distinguish normal tissues from cancers and circumvent this problem, the current 
study did not identify a Reactive IHC biomarker from the RPPA panel of proteins for the 
cancer or the stromal compartments. Although we presented some evidence (increased α-
SMA and stromal cell density) that the stroma may be distinctive, additional molecular 
studies are required to know whether the stroma itself is altered in Reactive cancers. In the 
current study, protein expression differences by RPPA appeared to be solely attributed to the 
intra-tumoral stromal content. Thus, our study suggests that an effective and practical 
biomarker to identify Reactive breast cancers in clinical practice may be intra-tumoral 
stromal content by imaging. In our imaging studies, we discovered that stromal content was 
bimodal, and a threshold of 48% by area could identify most Reactive breast cancers (Fig. 
2B, 93% sensitivity, 67% specificity). However, using the thresholds selected by the TCGA 
pathology team for manual scoring, a 75% cutoff had poor sensitivity (20%), and a 25% 
cutoff had no specificity (0%) for predicting Reactive breast cancers. Interestingly, in 
another imaging study of ER-positive breast cancers, the optimal threshold to segregate 
cases by clinical outcomes was approximately 50% intra-tumoral stromal content by area 
(9). Based on our results and those of others (8), we conclude that a 50% threshold may have 
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prognostic value for clinical outcomes in ER-positive/HER2-negative breast cancers but 
requires testing in a prospective clinical trial. Another choice for histopathological 
classification of Reactive breast cancers could be neoplastic tubule formation in IDC, ER-
pos/HER2-neg cases; we demonstrated a strong association of tubule formation with intra-
tumoral stromal content within the TCGA cohort (Fig. 3E). However, intra-tumoral stromal 
content is a more universal criteria because many Reactive cancers are also ILC or ILC/IDC 
mixed cases where neoplastic tubule formation cannot predict patient outcomes.
In summary, the subtyping of breast cancer by high stromal protein content has the potential 
to identify tumors with the best clinical outcomes. This information could be useful in 
assessing risk of relapse, especially within the heterogeneous group of ER-positive/HER2-
negative breast cancers. This study sets the stage for future studies that will be able to more 
accurately understand the biology of the disease and thus determine the most effective, 
personalized treatment options for all breast cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational Relevance
Improved biomarker tests are required to minimize overdiagnosis and overtreatment of 
breast cancers. A number of pathological criteria have been established to differentiate 
indolent or aggressive behavior, such as Nottingham grade of cancer cells. However, the 
effects of the tumor microenvironment on patient outcomes have not been integrated into 
pathologic criteria. In the current study, the Reactive subtype of breast cancer, identified 
by reverse phase protein arrays, was demonstrated to indicate a favorable outcome. The 
lowest risk tumors, typically ER-positive breast cancer tumors, were more likely to have 
high expression of stromal proteins, high intra-tumoral stromal volume, and increased 
cell density within the stromal compartment. ER-positive/HER2-negative disease with a 
Reactive protein signature had a high intra-tumoral stromal content and an excellent 
prognosis.
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Figure 1. 
Subtyping of breast cancers by RPPA. A, Heatmap by unsupervised consensus clustering of 
protein lysates analyzed for protein expression by RPPA for TCGA breast cancers (n = 771 
core cases). Clinical biomarkers: positive (red) or negative (green). Histopathology: IDC 
(red), ILC (green), or other (grey). mRNA subtyping by PAM50: Luminal A (black), 
Luminal B (blue), HER2-enriched (orange), Normal-like (green), and Basal-like (purple). 
CDH1 mutation: Yes (black), No (grey). Unknowns (white). The approximate locations of 
clinical biomarkers and other proteins are marked. B, Selected differentially-expressed 
proteins between cluster II (Reactive) and the other clusters. Boxplots are drawn with the 
Tukey method. ANOVA and Holm-Sidak's multiple comparison tests were performed. Only 
statistically significant comparisons to cluster II are reported. ***, P ≤ 0.001. C, Kaplan-
Meier survival curves for RPPA clusters in (A).
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Figure 2. 
Reactive breast cancers had the highest stromal content independently of ILC/IDC 
classification. A, α-SMA IHC staining with tissue and cell segmentation maps for an 
example case, A1H3. Tissues were segmented into cancer (red), stroma (yellow), empty 
(blue) using InForm 2.0 (Vectra). Images were selected to include those representing the 
core invasive tumor, excluding images with edge artifacts and structures unrelated to the 
tumor including normal ducts and DCIS. Percent stroma determined by area (B) and by cell 
counting (C). D, Stromal cell density was calculated from the absolute stromal area and cell 
counts within the compartment. ILC cases were selected from all available sections with 
clinical data and matching RPPA classification (n = 21). ILC includes ILC and ILC mixed 
cases. Representative IDC cases for RPPA subtypes for (B), (C), and (D) (n = 4 ea; Luminal, 
Reactive, and Basal) were selected from available cases based on silhouette analysis. E, 
Paired correlation of InForm stromal area from (B) and manual pathologist scoring of 
stromal area. F, Stromal content of cancers separated by histopathology and RPPA subtype 
as determined by manual scoring (n = 70 for ILC, n = 331 for IDC). Symbols and error bars 
represent the average ± one standard deviation. Statistical analyses (paired Student's t-test, 
unpaired Student's t-test, paired Spearman correlation, or ANOVA as appropriate) were 
performed within histopathology groups. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001
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Figure 3. 
Stromal content association with histopathology, Nottingham grade, and differentiation. A, 
Intra-tumoral stromal (ITS) content of TCGA breast cancers separated by histopathology (n 
= 70 for ILC, n = 352 for IDC). ILC includes ILC and ILC mixed cases. B, Nottingham 
grade of ER-pos/HER2-neg cases separated by histopathology and stromal content (n = 61 
for ILC, n = 238 for IDC). C, α-SMA staining of representative luminal and stromal breast 
cancers (TCGA cases A1J1 and A1H3) as determined by silhouette analysis. D, Cancer cells 
(top, black arrow marks cancer epithelium) and normal breast ducts (bottom, black arrow 
marks myoepithelium) from TCGA case A1XR stained with α-SMA. E, Association of ITS 
score with tubule formation score for TCGA breast cancers (n = 261, IDC, ER-pos/HER2-
neg). ANOVA and Holm-Sidak's multiple comparison tests were performed for (A), (B), and 
(E) assuming the pathology score was a continuous variable. *, P ≤ 0.05; ***, P ≤ 0.001
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Table 1
Association of clinical characteristics to the RPPA Reactive subtype for ER-positive/HER2-negative and all 
breast cancers, TCGA core cohort.
ER-pos/HER2-neg All
Characteristic No. Reactive % χ2 P No. Reactive % χ2 P
No. of Patients 125 29.9 – 210 27.1 –
Age 0.75 0.831
    < 50 years 35 31.5 58 26.4
    ≥ 50 years 90 29.3 152 27.4
Tumor size at diagnosis (TNM) 0.16 0.522
    T0/T1/T2 97 28.3 163 26.0
    T3/T4 28 37.3 38 29.2
Lymph Node 1.0 0.441
    Negative 49 30.8 90 29.4
    Positive 63 31.3 88 26.2
Histopathology <0.001 <0.001
    IDC 62 21.5 111 20.1
    ILC/Mixed 57 57.0 77 55.0
Nottingham Grade* 0.009 <0.001
    1 14 31.8 15 28.8
    2 68 33.7 96 31.2
    3 14 17.3 32 14.3
PAM50 Subtype** <0.001 <0.001
    Luminal A 104 36.2 139 36.7
    Luminal B 12 10.9 18 10.5
    HER2-enriched 0 0.0 4 7.5
    Normal 8 88.9 18 81.8
    Basal 0 0.0 16 12.7
TP53 mutation 0.028 <0.001
    WT 104 32.7 150 30.5
    Mut 12 18.2 29 14.6
CDH1 mutation <0.001 <0.001
    WT 87 26.3 139 22.6
    Mut 29 54.7 40 54.1
*
For Nottingham grading, grades 1 and 2 pooled were compared to grade 3 cases.
**
For PAM50 intrinsic subtyping, Luminal A subtype was compared to other subtypes pooled (Luminal B, HER2-enriched, and Basal).
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